200 related articles for article (PubMed ID: 19347234)
21. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes.
Sheng WS; Hu S; Min X; Cabral GA; Lokensgard JR; Peterson PK
Glia; 2005 Jan; 49(2):211-9. PubMed ID: 15390091
[TBL] [Abstract][Full Text] [Related]
22. Synthetic cannabinoids reduce the inflammatory activity of microglia and subsequently improve neuronal survival in vitro.
Young AP; Denovan-Wright EM
Brain Behav Immun; 2022 Oct; 105():29-43. PubMed ID: 35764268
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoids and cardiovascular disease: the outlook for clinical treatments.
Ashton JC; Smith PF
Curr Vasc Pharmacol; 2007 Jul; 5(3):175-85. PubMed ID: 17627561
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoids and neuroprotection in motor-related disorders.
de Lago E; Fernández-Ruiz J
CNS Neurol Disord Drug Targets; 2007 Dec; 6(6):377-87. PubMed ID: 18220777
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain.
Toth CC; Jedrzejewski NM; Ellis CL; Frey WH
Mol Pain; 2010 Mar; 6():16. PubMed ID: 20236533
[TBL] [Abstract][Full Text] [Related]
26. Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.
Vendel E; de Lange EC
Neuromolecular Med; 2014 Sep; 16(3):620-42. PubMed ID: 24929655
[TBL] [Abstract][Full Text] [Related]
27. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.
Docagne F; Muñetón V; Clemente D; Ali C; Loría F; Correa F; Hernangómez M; Mestre L; Vivien D; Guaza C
Mol Cell Neurosci; 2007 Apr; 34(4):551-61. PubMed ID: 17229577
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis.
Marchalant Y; Brothers HM; Norman GJ; Karelina K; DeVries AC; Wenk GL
Neurobiol Dis; 2009 May; 34(2):300-7. PubMed ID: 19385063
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoids in depressive disorders.
Poleszak E; Wośko S; Sławińska K; Szopa A; Wróbel A; Serefko A
Life Sci; 2018 Nov; 213():18-24. PubMed ID: 30290188
[TBL] [Abstract][Full Text] [Related]
30. Role of cannabinoids in the development of fatty liver (steatosis).
Purohit V; Rapaka R; Shurtleff D
AAPS J; 2010 Jun; 12(2):233-7. PubMed ID: 20204561
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J
Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181
[TBL] [Abstract][Full Text] [Related]
32. ACPA and JWH-133 modulate the vascular tone of superior mesenteric arteries through cannabinoid receptors, BK
López-Dyck E; Andrade-Urzúa F; Elizalde A; Ferrer-Villada T; Dagnino-Acosta A; Huerta M; Osuna-Calleros Z; Rangel-Sandoval C; Sánchez-Pastor E
Pharmacol Rep; 2017 Dec; 69(6):1131-1139. PubMed ID: 29128791
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.
Stella N
Glia; 2010 Jul; 58(9):1017-30. PubMed ID: 20468046
[TBL] [Abstract][Full Text] [Related]
34. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL
J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease.
Little JP; Villanueva EB; Klegeris A
Mini Rev Med Chem; 2011 Jun; 11(7):582-90. PubMed ID: 21699489
[TBL] [Abstract][Full Text] [Related]
36. Recent data on cannabinoids and their pharmacological implications in neuropathic pain.
Coman OA; Paunescu H; Coman L; Badarau A; Fulga I
J Med Life; 2008; 1(4):365-75. PubMed ID: 20108515
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia.
Schmidt W; Schäfer F; Striggow V; Fröhlich K; Striggow F
Neuroscience; 2012 Dec; 227():313-26. PubMed ID: 23069763
[TBL] [Abstract][Full Text] [Related]
38. Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence.
Jensen B; Chen J; Furnish T; Wallace M
Curr Pain Headache Rep; 2015 Oct; 19(10):50. PubMed ID: 26325482
[TBL] [Abstract][Full Text] [Related]
39. Involvement of ERK1/2, cPLA2 and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists.
Ribeiro R; Wen J; Li S; Zhang Y
Prostaglandins Other Lipid Mediat; 2013 Jan; 100-101():1-14. PubMed ID: 23219970
[TBL] [Abstract][Full Text] [Related]
40. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
